• Anton P Porsteinsson, Jessica S Smith, Melanie A Keltz, and Inga M Antonsdottir.
• University of Rochester School of Medicine and Dentistry, 435 East Henrietta Road, Rochester, NY14620, USA.
• Expert Rev Neurother. 2014 Sep 1; 14 (9): 969-71.

AbstractNeuropsychiatric symptoms (NPS) are a major concern in the treatment of Alzheimer's disease. Historically, NPS are difficult to treat effectively due to a high side-effect burden associated with commonly used medications, such as atypical antipsychotics. Non-pharmacological treatment approaches have become the first line option. However, when such treatment fails, pharmacological options are often used. Thus, a push toward finding safer alternative pharmacological treatments has occurred. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs) have shown promise in clinical trials for alleviating the burden of NPS. Lower overall agitation and caregiver stress has been reported to correlate to treatment with the SSRI citalopram. However, certain side effects of citalopram, such as QTc interval prolongation and increased cognitive decline, carry clinical concern and should be weighed when prescribing their use.

16 keywords...

hide…